Table 3.
Polygenic risk scores | Remission status (N = 143) | Relapse status (N = 73) | ||||
---|---|---|---|---|---|---|
OR [95% CI] | p value | Per-P | OR [95% CI] | p value | Per-P | |
ALZ (IGAP 1) [38] | 1.34 [0.90, 1.99] | 0.15 | 0.45 | 0.006 [0.0002, 0.14] | 0.002 | 0.01* |
ALZ (IGAP 1–2 meta-analysis) [38] | 0.91 [0.63, 1.32] | 0.63 | 0.91 | 0.38 [0.18, 0.80] | 0.01 | 0.03* |
ALZ [39] | 1.53 [0.91, 2.57] | 0.11 | 0.39 | 0.73 [0.40, 1.36] | 0.32 | 0.81 |
BPD [37] | 2.39 [0.16, 36.14] | 0.53 | 0.96 | – | – | –a |
MDD (PGC) [34] | 1.10 [0.68, 1.79] | 0.70 | 0.99 | 0.64 [0.34, 1.20] | 0.16 | 0.40 |
MDD (PGC) [33] | 0.85 [0.56, 1.28] | 0.43 | 0.66 | 0.72 [0.38, 1.37] | 0.32 | 0.51 |
AD non-remission (PGC) [35] | 0.70 [0.41, 1.20] | 0.19 | 0.61 | 1.81 [0.93, 3.51] | 0.08 | 0.33 |
AD improvement (PGC) [35] | 1.95 [1.20, 3.17] | 0.007 | 0.04* | 1.92 [1.05, 3.53] | 0.03 | 0.17 |
SCZ [36] | 1.56 [1.04, 2.33] | 0.03 | 0.09 | 0.82 [0.36, 1.84] | 0.62 | 0.96 |
All stroke [40] | 1.46 [0.97, 2.21] | 0.07 | 0.26 | 0.19 [0.04, 0.88] | 0.03 | 0.15 |
Ischemic stroke | 0.81 [0.41, 1.58] | 0.54 | 0.96 | 0.27 [0.06, 1.28] | 0.10 | 0.37 |
Cardioembolic stroke | 1.80 [0.88, 3.71] | 0.11 | 0.39 | 0.15 [0.01, 1.58] | 0.11 | 0.35 |
Large vessel stroke | 2.15 [0.35, 13.22] | 0.41 | 0.90 | 1.86 [0.64, 5.41] | 0.25 | 0.70 |
Small vessel stroke | 1.33 [0.73, 2.41] | 0.36 | 0.85 | – | – | –a |
AD, antidepressant; ALZ, Alzheimer’s disease; BPD, bipolar disorder; CI, confidence interval; IGAP, the International Genomics of Alzheimer’s Project; MDD, major depressive disorder; OR, odds ratio; p, p value; Per-P, permutation p value; PGC, Psychiatric Genomics Consortium; SCZ, schizophrenia.
*p < 0.05 (number of permutation testing = 10,000).
aModel did not converge.